BerGenBio Reports the First Patient Dosing of Bemcentinib in the P-Ib/IIa Trial as 1L Treatment of Non-Small Cell Lung Cancer
Shots:
- The first patient has been dosed in a P-Ib/IIa trial evaluating bemcentinib + pembrolizumab and doublet CT in patients with NSCLC harboring STK11 mutations (STK11m)
- The P-Ib portion of the study will evaluate the safety and feasibility of bemcentinib + pembrolizumab and doublet CT in 1L advanced/metastatic non-sq. NSCLC patients, regardless of STK11 status while the P-IIa expansion part will assess the efficacy in patients with STK11 mutations
- Bemcentinib is a potent selective small molecule inhibitor of Axl over-expressed in many metastatic solid tumors and has been identified as a marker of a poor prognosis in patients with NSCLC & showed synergistic activity with docetaxel in vivo models of NSCLC
Ref: PRNewswire | Image: BerGenBio
Related News:- BerGenBio Reports P-II Trial Results of BGB324 (bemcentinib) as 2L Treatment of Non-Small Cell Lung Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
